Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes
Top Cited Papers
- 1 March 2004
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 3 (3) , 215-225
- https://doi.org/10.1038/nrd1331
Abstract
Highly active antiretroviral therapy (HAART) based on combinations of drugs that target key enzymes in the life-cycle of human immunodeficiency virus (HIV) has considerably reduced morbidity and mortality from HIV infection since its introduction in the mid-1990s. However, the growing problem of the emergence of HIV strains that are resistant not only to individual drugs, but to whole drug classes, means that agents with new mechanisms of action are needed. Here, we describe the discovery and development of enfuvirtide (Fuzeon), the first drug to inhibit the entry of HIV-1 into host cells.Keywords
This publication has 48 references indexed in Scilit:
- Enfuvirtide (T‐20) Cross‐Reactive Glycoprotein 41 Antibody Does Not Impair the Efficacy or Safety of EnfuvirtideThe Journal of Infectious Diseases, 2003
- Injection site reactions with the HIV-1 fusion inhibitor enfuvirtideJournal of the American Academy of Dermatology, 2003
- Patient Acceptance of Self-Injected Enfuvirtide at 8 and 24 WeeksHIV Research & Clinical Practice, 2003
- Novel Therapies Based on Mechanisms of HIV-1 Cell EntryNew England Journal of Medicine, 2003
- A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapyAIDS, 2003
- Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy EraMedical Decision Making, 2003
- The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected AdultsAIDS Research and Human Retroviruses, 2002
- Initial Virological and Immunologic Response to Highly Active Antiretroviral Therapy Predicts Long‐Term Clinical OutcomeClinical Infectious Diseases, 2001
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences, 1994
- A Synthetic Peptide from HIV-1 gp41 Is a Potent Inhibitor of Virus-Mediated Cell—Cell FusionAIDS Research and Human Retroviruses, 1993